2020 On-site introduces new solutions for delayed clinical trials
Category: #health  By Pankaj Singh  Date: 2020-06-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

2020 On-site introduces new solutions for delayed clinical trials

The COVID-19 pandemic has significantly impacted the existing ecosystem of clinical trials as a whole. Except for COVID-19, most of the on-going or new clinical studies have essentially delayed or stopped in several countries across the world.

In a bid to streamline the clinical trial ecosystem involving ophthalmic endpoints, 2020 On-site, the America-based provider of on-site vision care for schools and businesses, has reportedly expanded its convenience-based eye care service to include an exclusive solution for investors, trail sponsors, sites, patients, and investigators.

According to sources, to prevent delays in clinical trials, 2020 On-site is offering a truly patient-centric solution for clinical trials involving ophthalmic endpoints. The company’s professionals and optometrists will visit patients in their homes anywhere in America, offering a safe and flexible way for the continuation of clinical trials.

Moreover, the company’s expertise in securely collecting vital optometric data, patient care, and cutting-edge IT systems with built-in redundancies will ensure the integrity of every clinical trial. Its logistics capabilities will also help its mobile clinicians to visit patients across the nation in just a few days.

Speaking on which, Alexis McLaughlin, CEO of 2020 On-site said that clinical trials are vital to aid the advancement of novel medicines and the company’s mobile clinic can conveniently meet the demand. The company believes that on-site mobile service for clinical care may become the new standard for some treatments or patients, Mr. McLaughlin added.

For the record, established in 2014 in Boston, the company offers on-site optometry services through cutting-edge mobile vision clinics. 2020 On-site introduced its new service in May and deployed its mobile clinic to aid a nationwide clinical study for a major biotechnology company. Since then, it has traversed around 8,000 miles to visit patients in 12 states.

Source Credit -https://uk.finance.yahoo.com/news/2020-launches-first-direct-patient-185400396.html

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...